{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-268477","form_type":"8-K","ticker":"MBX","cik":"0001776111","company_name":"MBX Biosciences, Inc.","filed_at":"2026-06-12T11:05:58+00:00","discovered_at":"2026-06-12T11:10:00.303051+00:00","generated_at":"2026-06-12T11:10:11.331733+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"MBX Biosciences announces sustained one-year data for once-weekly canvuparatide in hypoparathyroidism","bullets":["57% of evaluable patients (31/54) achieved responder status at one year, comparable to 63% at 12 weeks in Phase 2 Avail trial.","PK profile supports once-weekly dosing with peak-to-trough ratio of ~1.3 over one week, ensuring stable exposure.","Mean eGFR increased from baseline at Week 12 and remained improved through one year; urine calcium decreased and stayed normal.","Canvuparatide was well tolerated; no treatment-related serious adverse events; injection site reactions in 10% of OLE patients.","Phase 3 pivotal trial remains on track to initiate in Q3 2026; 90% of OLE patients continued treatment at one year."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-268477","json":"https://secwatch.observer/filing/0001193125-26-268477.json","markdown":"https://secwatch.observer/filing/0001193125-26-268477.md","text":"https://secwatch.observer/filing/0001193125-26-268477.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1776111/000119312526268477/0001193125-26-268477-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1776111/000119312526268477/mbx-20260612.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T11:10:11.331733+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}